We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Restored European Patent May Upset Generic Fosamax Market
Restored European Patent May Upset Generic Fosamax Market
April 3, 2007
The reinstatement of Merck’s Fosamax patent in Europe could spell trouble for generic firms who market their own versions of the
drug in that part of the world, according to A.G. Edwards & Sons.